Clinical Trial Update: Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept study of ACT001 in adults with recurrent glioblastoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ACT001

Snippet

Sponsor: National Neuroscience Institute | Conditions: Recurrent Glioblastoma | Phase 2 | Status: SUSPENDED